[WS(P)26] Systemic Immune Diseases

[WS26-06-O/P] Development of the anti-human TLR7 monoclonal antibody for therapeutic intervention in systemic lupus erythematosus

^○Ryutaro Fukui¹, Yusuke Murakami^2,1, Atsuo Kanno¹, Yuji Motoi¹, Atsushi Manno⁴, Tomohiro Honda⁵, Shinnosuke Yamada⁵, Jun Ishiguro⁶, Kensuke Nakamura⁷, Giorgio Senaldi⁸, Toshiyuki Shimizu³, Kensuke Miyake¹ (1.The Institute of Medical Science, The University of Tokyo, 2.Department of Pharmaceutical Sciences & Research Institute of Pharmaceutical Sciences, Musashino University, 3.Graduate School of Pharmaceutical Sciences, The University of Tokyo, 4.Discovery Research Laboratories II, Daiichi Sankyo Co., Ltd., 5.Translational Science Department II, Daiichi Sankyo Co., Ltd., 6.Discovery Research Laboratories V, Daiichi Sankyo Co., Ltd., 7.Modality Research Laboratories II, Daiichi Sankyo Co., Ltd., 8.Clinical development, Daiichi Sankyo, Inc.)

キーワード：

Antibody drug、Toll-like receptor 7、Innate immunity、Systemic lupus erythematosus、Autoimmune disease

閲覧にはパスワードが必要です

ログイン

または